EA003675B1 - Белки, связывающие интерлейкин-18, их получение и применение - Google Patents

Белки, связывающие интерлейкин-18, их получение и применение Download PDF

Info

Publication number
EA003675B1
EA003675B1 EA200000216A EA200000216A EA003675B1 EA 003675 B1 EA003675 B1 EA 003675B1 EA 200000216 A EA200000216 A EA 200000216A EA 200000216 A EA200000216 A EA 200000216A EA 003675 B1 EA003675 B1 EA 003675B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
seq
amino acid
acid sequence
nucleic acid
Prior art date
Application number
EA200000216A
Other languages
English (en)
Russian (ru)
Other versions
EA200000216A1 (ru
Inventor
Даниела Новик
Чарльз Динарелло
Менахем Рубинштейн
Соо Хиун Ким
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко. Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Йеда Рисерч Энд Дивелопмент Ко. Лтд filed Critical Йеда Рисерч Энд Дивелопмент Ко. Лтд
Publication of EA200000216A1 publication Critical patent/EA200000216A1/ru
Publication of EA003675B1 publication Critical patent/EA003675B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
EA200000216A 1997-08-14 1998-08-13 Белки, связывающие интерлейкин-18, их получение и применение EA003675B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use
PCT/IL1998/000379 WO1999009063A1 (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins, their preparation and use

Publications (2)

Publication Number Publication Date
EA200000216A1 EA200000216A1 (ru) 2000-08-28
EA003675B1 true EA003675B1 (ru) 2003-08-28

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000216A EA003675B1 (ru) 1997-08-14 1998-08-13 Белки, связывающие интерлейкин-18, их получение и применение

Country Status (28)

Country Link
US (4) US6605280B1 (enExample)
EP (1) EP1003781B1 (enExample)
JP (1) JP4272348B2 (enExample)
KR (1) KR100687388B1 (enExample)
CN (1) CN1243021C (enExample)
AR (2) AR013422A1 (enExample)
AT (1) ATE443719T1 (enExample)
AU (1) AU755794B2 (enExample)
BG (1) BG65519B1 (enExample)
BR (1) BRPI9811940B8 (enExample)
CA (1) CA2298855C (enExample)
CY (1) CY1109664T1 (enExample)
CZ (1) CZ300818B6 (enExample)
DE (2) DE1003781T1 (enExample)
DK (1) DK1003781T3 (enExample)
EA (1) EA003675B1 (enExample)
EE (1) EE05538B1 (enExample)
ES (1) ES2149149T3 (enExample)
HU (1) HU226698B1 (enExample)
IL (5) IL121860A0 (enExample)
NO (1) NO327240B1 (enExample)
NZ (1) NZ502392A (enExample)
PL (1) PL206070B1 (enExample)
PT (1) PT1003781E (enExample)
SI (1) SI1003781T1 (enExample)
SK (1) SK287194B6 (enExample)
UA (1) UA75862C2 (enExample)
WO (1) WO1999009063A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
CN1322897C (zh) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Il－18抑制剂的应用
CZ300792B6 (cs) * 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
CA2424983A1 (en) * 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2295332T3 (es) * 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
MXPA03010575A (es) * 2001-05-16 2005-03-07 Yeda Res & Dev Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis.
PT1390070T (pt) * 2001-05-25 2017-03-01 Ares Trading Sa Utilização de inibidores de il-18 para o tratamento ou prevenção de lesões do snc
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
WO2003080104A2 (en) * 2002-03-22 2003-10-02 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
EP1621616A4 (en) * 2003-04-30 2007-07-04 Japan Science & Tech Agency HUMAN ANTI-HUMAN INTERLEUKIN-18 ANTIBODY, FRAGMENT AND METHOD FOR THEIR USE
DK1622939T3 (da) 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
AU2004291341B2 (en) 2003-11-05 2010-08-05 Ares Trading S.A. Process for the purification of IL-18 binding protein
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2004290049B2 (en) 2003-11-12 2011-09-29 The Regents Of The University Of Colorado Compositions and methods for regulation of tumor necrosis factor-alpha
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
PL1720979T3 (pl) * 2004-03-01 2008-03-31 Ares Trading Sa Zastosowanie podłoża pozbawionego surowicy do hodowli komórkowej do wytwarzania IL-18BP w komórkach ssaków
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
DE602005009827D1 (de) 2004-06-29 2008-10-30 Ares Trading Sa Verfahren zur aufreinigung von il-18-bindendem protein
EP2267024B1 (en) * 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US8128920B2 (en) * 2005-06-03 2012-03-06 Merck Serono Sa Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
SI1891088T1 (sl) * 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2941310A4 (en) * 2013-01-02 2016-08-24 Wilsa Inc METHOD AND DEVICE FOR CONDITIONING LIQUIDS
KR102512797B1 (ko) 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
PE20251671A1 (es) * 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
WO2024148243A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
WO1998022137A1 (en) 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
CN1269722A (zh) 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
CA2297157A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in testis and other tissues
DK1000151T3 (da) 1997-08-01 2006-10-02 Serono Genetics Inst Sa 5'EST'er for secernerede proteiner udtrykt i forskellige væv
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
BR9910023A (pt) 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
SK1762000A3 (en) 2000-09-12
ES2149149T1 (es) 2000-11-01
IL121860A0 (en) 1998-02-22
US20100010200A1 (en) 2010-01-14
HUP0003533A3 (en) 2003-08-28
CZ2000490A3 (cs) 2000-08-16
CZ300818B6 (cs) 2009-08-19
AR062867A2 (es) 2008-12-10
US7799541B2 (en) 2010-09-21
US20060154294A1 (en) 2006-07-13
BRPI9811940B8 (pt) 2021-07-06
EP1003781A1 (en) 2000-05-31
EA200000216A1 (ru) 2000-08-28
HUP0003533A2 (hu) 2001-01-29
PT1003781E (pt) 2009-10-26
NO20000700D0 (no) 2000-02-11
DE69841175D1 (de) 2009-11-05
PL338647A1 (en) 2000-11-06
KR100687388B1 (ko) 2007-02-26
BG104149A (bg) 2000-08-31
IL122134A0 (en) 1998-04-05
NZ502392A (en) 2002-12-20
US6605280B1 (en) 2003-08-12
AU755794B2 (en) 2002-12-19
BG65519B1 (bg) 2008-10-31
KR20010022900A (ko) 2001-03-26
US8436148B2 (en) 2013-05-07
DE1003781T1 (de) 2001-01-11
WO1999009063A1 (en) 1999-02-25
EE200000073A (enExample) 2000-10-16
JP4272348B2 (ja) 2009-06-03
US20040037829A1 (en) 2004-02-26
ES2149149T3 (es) 2009-12-01
CY1109664T1 (el) 2014-08-13
PL206070B1 (pl) 2010-06-30
IL134523A (en) 2011-09-27
US7101689B2 (en) 2006-09-05
EE05538B1 (et) 2012-04-16
NO327240B1 (no) 2009-05-18
IL134523A0 (en) 2001-04-30
DK1003781T3 (da) 2010-01-25
JP2001514876A (ja) 2001-09-18
SK287194B6 (sk) 2010-03-08
IL125463A0 (en) 1999-03-12
NO20000700L (no) 2000-04-14
BRPI9811940A (pt) 2000-09-05
AR013422A1 (es) 2000-12-27
ATE443719T1 (de) 2009-10-15
CN1267307A (zh) 2000-09-20
CN1243021C (zh) 2006-02-22
UA75862C2 (uk) 2006-06-15
AU8746098A (en) 1999-03-08
CA2298855C (en) 2014-05-27
EP1003781B1 (en) 2009-09-23
CA2298855A1 (en) 1999-02-25
BRPI9811940B1 (pt) 2011-10-04
SI1003781T1 (sl) 2009-12-31
HK1028773A1 (en) 2001-03-02
HU226698B1 (en) 2009-07-28

Similar Documents

Publication Publication Date Title
EA003675B1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
KR100386046B1 (ko) 폴리펩티드 및 이를 암호화하는 핵산
AU2003294488B2 (en) Use of HMGB fragments as anti-inflammatory agents
ES2284214T3 (es) Nuevas moleculas de la familia de las proteinas tango-77 y usos de las mismas.
KR100620334B1 (ko) 헤르페스 심플렉스 바이러스 유입 매개체에 대한 리간드및 사용 방법
CA2181062A1 (en) Diagnosis of metastatic cancer by the mts-1 gene
MX2007005612A (es) Novedosas composiciones y metodos para el tratamiento de enfermedades inmuno relacionadas.
ES2316175T3 (es) Antigenos especificos de plaquetas y sus usos farmacologicos.
Shinohara et al. S-antigen: structure, function and experimental autoimmune uveitis (EAU)
ES2263865T3 (es) Homologo humano de neurotrimina.
MXPA05003440A (es) Uso de antigenos a33 y jam-it.
JP2002532092A (ja) プロスタサイクリン刺激因子−２
JP2006521810A (ja) 免疫関連疾患の治療のための新規組成物と方法
US20080219985A1 (en) Prok2 antagonists and methods of use
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
AU3926893A (en) Ifn receptors recognition factors, protein sequences and methods of use thereof
US7060682B2 (en) Receptor recognition factors, protein sequences and methods of use thereof
ES2317967T5 (es) Proteína GAS-6 (GROWTH ARREST-SPECIFIC GENE 6) humana y ácidos nucleicos que la codifican
US20060051366A1 (en) Use of soluble CD26 as inhibitor of angiogenesis and inflammation
AU2003204018B2 (en) Novel PR0337 polypeptides and nucleic acids encoding same
WO2008072000A2 (en) Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover
EA005242B1 (ru) Способ лечения артрита при использовании блокирующего моноклонального антитела к интегрину vla-1 или его фрагмента
KR20000016598A (ko) 신규단백질및그제조방법
AU2007205777A1 (en) Use of HMGB fragments as anti-inflammatory agents

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU